Clinical trial
Fuzeon Viral Decay Pilot Study
NCT00334022 · Canadian Immunodeficiency Research Collaborative, Other · Completed
Key facts
| NCT number | NCT00334022 |
|---|---|
| Title | Fuzeon Viral Decay Pilot Study |
| Official title | A Pilot Randomized Controlled Trial of Adding Enfuvirtide to Standard Combination Antiretroviral Therapy in HIV-infected Individuals With Full Virologic Suppression to Further Suppress Proviral HIV DNA |
| Lead sponsor | Canadian Immunodeficiency Research Collaborative, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV-1 |
| Intervention type | Drug |
| Interventions | enfuvirtide |
| Enrollment | 18 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jan 1, 2010 |
| First posted | Jun 6, 2006 |
| Last update posted | Jun 5, 2012 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: